¼¼°èÀÇ ¼±ÅÃÀû ¿¡½ºÆ®·Î°Õ ¼ö¿ëü ºÐÇØÁ¦(SERD) ½ÃÀå - ½ÃÀå ±âȸ, Á¦³×¸¯ ÀǾàǰ °¡¿ë¼º, ¾à¹° ¿ë·®, °¡°Ý, ÀÓ»ó½ÃÇè µ¿Çâ(2030³â)
Global Selective Estrogen Receptor Degrader (SERDs) Market Opportunity, Generic Availability, Drug Dosage, Price & Clinical Trials Insight 2030
»óǰÄÚµå : 1759331
¸®¼­Ä¡»ç : KuicK Research
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 110 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 2,800 £Ü 3,854,000
PDF (Single User License) help
º¸°í¼­ PDF¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 1ȸ¸¸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 4,200 £Ü 5,782,000
PDF (Multi-User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ ¼±ÅÃÀû ¿¡½ºÆ®·Î°Õ ¼ö¿ëü ºÐÇØÁ¦(SERD) ½ÃÀå - ½ÃÀå ±âȸ, Á¦³×¸¯ ÀǾàǰ °¡¿ë¼º, ¾à¹° ¿ë·®, °¡°Ý, ÀÓ»ó½ÃÇè µ¿Çâ(2030³â) º¸°í¼­ÀÇ Á¶»ç °á°ú ¹× ÁÖ¿ä ³»¿ë

2000³â´ë ÃÊ¹Ý ÀÌÈÄ ¼±ÅÃÀû ¿¡½ºÆ®·Î°Õ ¼ö¿ëü ºÐÇØÁ¦(SERD)¸¦ µÑ·¯½Ñ ȯ°æÀº Ç÷纣½ºÆ®¶õÆ®ÀÇ µµÀÔÀ» ½ÃÀÛÀ¸·Î Å©°Ô º¯È­Çß½À´Ï´Ù. ¿¡½ºÆ®·Î°ÕÀÇ ½ÅÈ£ Àü´ÞÀ» ¾ïÁ¦ÇÏ´Â ±âÁ¸ÀÇ ³»ºÐºñ Ä¡·áÁ¦¿Í ´Þ¸® SERD´Â ¿¡½ºÆ®·Î°Õ ¼ö¿ëü¸¦ Àû±ØÀûÀ¸·Î ºÐÇØÇÑ´Ù´Â »õ·Î¿î ÀåÁ¡À» °¡Á³½À´Ï´Ù. ÀÌ´Â ¼ö¿ëüÀÇ È°¼ºÀ» ¸ØÃß°Ô ÇÒ »Ó¸¸ ¾Æ´Ï¶ó, È£¸£¸ó ¼ö¿ëü ¾ç¼º HER2 À½¼º À¯¹æ¾Ï ¼¼Æ÷ÀÇ ÈÄ¼Ó Áõ½ÄÀ» Á¦ÇÑÇß½À´Ï´Ù. ȯÀÚµéÀÌ ¾Æ·Î¸¶Å¸Á¦ ¾ïÁ¦Á¦¿Í ¼±ÅÃÀû ¿¡½ºÆ®·Î°Õ ¼ö¿ëü Á¶ÀýÁ¦¿¡ ´ëÇÑ ³»¼ºÀ» °®°Ô µÇ¸é¼­ SERD´Â º¸´Ù È¿°úÀûÀ̰í Áö¼ÓÀûÀÎ Ä¡·áÁ¦·Î ºü¸£°Ô ´ëÁßÈ­µÇ¾ú½À´Ï´Ù.

AstraZeneca¿¡¼­ Faslodex¶ó´Â »óǰ¸íÀ¸·Î ÆÇ¸ÅµÇ°í ÀÖ´Â Ç÷纣½ºÆ®¶õÆ®´Â ¹Ì±¹ FDA µî ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎÀ» ¹ÞÀº ÃÖÃÊÀÇ SERDÀÔ´Ï´Ù. Ãʱ⿡´Â Ÿ¸ñ½ÃÆæ ³»¼º ȯÀÚ¸¦ À§ÇÑ ´Üµ¶¿ä¹ýÀ¸·Î »ç¿ëµÇ¾úÀ¸³ª, ºü¸£°Ô Àα⸦ ²ø¸é¼­ CDK4/6 ¾ïÁ¦Á¦¿Í °°Àº ´Ù¸¥ ¾à¹°°ú º´¿ë¿ä¹ýÀ¸·Î »ç¿ëµÇ±â ½ÃÀÛÇß½À´Ï´Ù. Ç÷纣½ºÆ®¶õÆ®´Â ÀÓ»óÀû ±Ù°ÅÀÇ Áõ°¡¿Í Àü ¼¼°èÀûÀÎ º¸±ÞÀ¸·Î HR+ Æó°æ ÈÄ À¯¹æ¾ÏÀÇ ÁÖ¿ä Ä¡·áÁ¦·Î ¼ºÀåÇß½À´Ï´Ù. ÇÏÁö¸¸, 2019³â Ç÷纣½ºÆ®¶õÆ®ÀÇ Æ¯Çã ¸¸·á·Î ÀÎÇØ Á¦³×¸¯ ÀǾàǰÀÌ Ãâ½ÃµÇ¸é¼­ Àú·ÅÇÑ °¡°ÝÀÇ Á¦Ç°ÀÌ ¼Ó¼Ó µîÀåÇØ ½ÃÀå ¿ªÇÐÀÌ Å©°Ô º¯È­Çß½À´Ï´Ù. Àü ¼¼°èÀûÀ¸·Î 25°³ ÀÌ»óÀÇ Á¦³×¸¯ ÀǾàǰÀÌ Ãâ½ÃµÇ¾î ÆÄ½º·Îµ¦½ºÀÇ ½ÃÀå Á¡À¯À²Àº °¨¼ÒÇÏ´Â ¹Ý¸é, º¹Á¦¾àÀÇ »ç¿ë·®Àº ±ÞÁõÇÏ¿© ÇöÀç Àüü »ç¿ë·®ÀÇ Àý¹Ý ÀÌ»óÀ» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù.

ÀÌ·¯ÇÑ º¯È­´Â 2023³â FDA°¡ ½ÂÀÎÇÑ ¿À¼¿µà(¿¤¶ó¼¼½ºÆ®¶õÆ®)ÀÇ ±â¼ú Çõ½ÅÀÇ °ø¹éÀ» °¡Á®¿Ô½À´Ï´Ù. ¿À¼¿µàÀÇ Æ¯Â¡Àº SERD °è¿­ Áß ÃÖÃÊ·Î °æ±¸Á¦¶ó´Â Á¡ÀÔ´Ï´Ù. Ç÷纣½ºÆ®¶õÆ® ±ÙÀ°Áֻ縦 ´ëüÇÒ ¼ö ÀÖ´Â °£ÆíÇÑ Ä¡·áÁ¦·Î, Ç¥ÁØ ³»ºÐºñ Ä¡·áÁ¦¿¡ ³»¼ºÀ» º¸ÀÌ´Â ESR1 À¯ÀüÀÚ º¯ÀÌ È¯ÀÚ ÀϺο¡°Ô¸¸ ½ÂÀεǾú½À´Ï´Ù. ¿À¼¿µàÀÇ ½ÂÀÎÀº ¸í¹éÇÑ ÀÓ»óÀû °ø¹éÀ» ¸Þ¿üÀ» »Ó¸¸ ¾Æ´Ï¶ó SERD¿¡ ´ëÇÑ Á¦¾à °³¹ßÀÚ¿Í ÀÓ»óÀǵéÀÇ °ü½ÉÀ» ´Ù½Ã ºÒ·¯ÀÏÀ¸Ä×½À´Ï´Ù.

¿À¼¿µà¿Í °°Àº °æ±¸¿ë SERD°¡ °¢±¤À» ¹ÞÀ¸¸é¼­ ÆÄÀÌÇÁ¶óÀÎ ºÕÀÌ ÀϾ°í ÀÖÀ¸¸ç, ¿©·¯ Â÷¼¼´ë È­ÇÕ¹°µéÀÌ Áß±â ¹× Èıâ ÀÓ»ó½ÃÇè¿¡ ÁøÀÔÇϰí ÀÖ½À´Ï´Ù. ³·Àº °¡¿ë¼º, ESR1 À¯ÀüÀÚ º¯ÀÌ È¯ÀÚ¿¡¼­ ³·Àº Ȱ¼º°ú °°Àº Ç®º£½ºÆ®¶õÆ®ÀÇ ÇѰ踦 ±Øº¹Çϱâ À§ÇØ °¢°¢ µ¶ÀÚÀûÀÎ Èĺ¸¹°ÁúÀ» ÃßÁøÇϰí ÀÖ½À´Ï´Ù. ÀÌ Áß °¡Àå À¯¸ÁÇÑ Èĺ¸¹°ÁúÀº ÀÓºê·ç³×½ºÆ®¶õÆ®, Áú·¹µ¥½ºÆ®¶õÆ®, Ä«¹ÌÁ¦½ºÆ®¶õÆ®, ÆÄ¶óÁ¦½ºÆ®¶õÆ®, Ÿ¶ó±Û·¹½ºÆ®¶õÆ® µîÀ̸ç, ÇöÀç ¸ðµÎ Èı⠴ܰ迡 ÀÖ½À´Ï´Ù. À̵é Áß ÀϺδ ´Üµ¶¿ä¹ý»Ó¸¸ ¾Æ´Ï¶ó ÁøÇ༺ Áúȯ¿¡¼­ ¿©·¯ ³»¼º °æ·Î¸¦ ±Øº¹Çϱâ À§ÇÑ ½Ãµµ·Î Ç¥Àû Ä¡·áÁ¦¿ÍÀÇ º´¿ëÅõ¿© ½ÃÇèµµ ÁøÇàµÇ°í ÀÖ½À´Ï´Ù.

¾Æ¸¶µµ °¡Àå ±â¼úÀûÀ¸·Î Âü½ÅÇÑ °ÍÀº Arvinas¿Í Pfizer°¡ °øµ¿ °³¹ßÇÑ PROTAC(Proteolysis Targeting Chimera) ¾à¹°ÀÎ vepdegestrantÀÏ °ÍÀÔ´Ï´Ù. º£ÇÁµ¥°Ô½ºÆ®¶õÆ®´Â °íÀüÀû ¼ö¿ëü ±æÇ× ÀÛ¿ëÀÌ ¾Æ´Ñ ¼¼Æ÷ °íÀ¯ÀÇ ´Ü¹éÁú ºÐÇØ ±âÀüÀ» ÀÌ¿ëÇÏ¿© ¿¡½ºÆ®·Î°Õ ¼ö¿ëü¸¦ ºÐÇØÇÕ´Ï´Ù. 3»ó VERITAC-2 ÀÓ»óÀ» ¼º°øÀûÀ¸·Î ¸¶Ä¡°í, 2025³â 6¿ù È­ÀÌÀÚ¿Í ¾Æ¸£ºñ³ª½º´Â FDA¿¡ ½Å¾à Çã°¡¸¦ ½ÅûÇÑ »óÅÂÀÔ´Ï´Ù. º£ÇÁµ¥°Ô½½¶õÆ®´Â PROTAC ±â¹Ý SERD·Î¼­´Â ÃÖÃÊ·Î Ãâ½ÃµÉ ¿¹Á¤À̸ç, Ç¥Àû ºÐÇØ Ä¡·áÀÇ »õ·Î¿î ÁöÆòÀ» ¿­°Ô µÉ °ÍÀÔ´Ï´Ù.

SERD Ç÷§ÆûÀº ´Üµ¶ »ç¿ë»Ó¸¸ ¾Æ´Ï¶ó CDK4/6 ¾ïÁ¦Á¦, PI3K ¾ïÁ¦Á¦, ½Å±Ô ºÐÀÚ Ç¥Àû ¾à¹° µî ´Ù¸¥ °è¿­ÀÇ ¾à¹°°úÀÇ º´¿ë¿ä¹ýµµ °í·ÁÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Àü·«Àº ¹ÝÀÀ ±â°£À» ¿¬ÀåÇÏ°í ³»¼º °æ·Î°¡ Ä¡·á È¿°ú¸¦ ´É°¡ÇÏ´Â °ÍÀ» ¹æÁöÇϱâ À§ÇØ °í¾ÈµÈ °ÍÀÔ´Ï´Ù.

SERDÀÇ °³¹ßÀº ÇöÀç À¯¹æ¾ÏÀ» Áß½ÉÀ¸·Î ÀÌ·ç¾îÁö°í ÀÖÁö¸¸, ³­¼Ò¾Ï, Àڱ󻸷¾Ï µî ¿¡½ºÆ®·Î°Õ ¼ö¿ëü¸¦ ¸Å°³·Î ÇÏ´Â ´Ù¸¥ ¾Ç¼ºÁ¾¾ç¿¡¼­µµ ÁÖ¸ñ¹Þ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀüÀÓ»ó ¿¬±¸¿¡¼­´Â ½Å°æÁ¤½ÅÁúȯ, ´ë»ç¼º Áúȯ, ¸¸¼º ÅëÁõ µî ºñÁ¾¾ç¿¡ ´ëÇÑ Àû¿ëÀÌ °ËÅäµÇ°í ÀÖ½À´Ï´Ù. ¾ÆÁ÷Àº Ãʱ⠴ܰèÀÌÁö¸¸, »õ·Î¿î °³Ã´Áö°¡ µÉ ¼ö ÀÖ´Â °¡´É¼ºÀ» °¡Áö°í ÀÖ½À´Ï´Ù.

SERD ½ÃÀåÀº ½ÂÀÎµÈ ÀǾàǰÀÇ ¼ö´Â ÀûÁö¸¸ ºü¸£°Ô ¹ßÀüÇϰí ÀÖÀ¸¸ç, ¿ªµ¿ÀûÀÌ°í °æÀï·Â ÀÖ´Â ½ÃÀåÀ¸·Î ¼ºÀåÇϰí ÀÖ½À´Ï´Ù. SERD´Â ÀÌ¹Ì ±íÀº ÆÄÀÌÇÁ¶óÀÎ, Á¤±³ÇÑ ÀÓ»ó½ÃÇè ÇÁ·Î±×·¥, PROTACs¿Í °°Àº ½Å±â¼úÀ» ÅëÇØ È£¸£¸ó ¼ö¿ëü ±â¹Ý ¾Ï Ä¡·áÀÇ Àü¸ÁÀ» Çõ½ÅÀûÀ¸·Î ¹Ù²Ù°í ÀÖ½À´Ï´Ù.

¼¼°èÀÇ ¼±ÅÃÀû ¿¡½ºÆ®·Î°Õ ¼ö¿ëü ºÐÇØÁ¦(SERD) ½ÃÀå¿¡ ´ëÇØ Á¶»çÇßÀ¸¸ç, ½ÃÀå °³¿ä, ÀûÀÀÁõº°, Áö¿ªº° µ¿Çâ, ½ÃÀå ÁøÀÔ ±â¾÷ ÇÁ·ÎÆÄÀÏ µîÀÇ Á¤º¸¸¦ ÀüÇØµå¸³´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ¼±ÅÃÀû ¿¡½ºÆ®·Î°Õ ¼ö¿ëü ºÐÇØÁ¦(SERD) ¼Ò°³

Á¦3Àå ¼±ÅÃÀû ¿¡½ºÆ®·Î°Õ ¼ö¿ëü ºÐÇØÁ¦ ÀûÀÀÁõº° ÀÀ¿ë

Á¦4Àå ¼±ÅÃÀû ¿¡½ºÆ®·Î°Õ ¼ö¿ëü ºÐÇØÁ¦ ½ÃÀå ºÐ¼®

Á¦5Àå ¼±ÅÃÀû ¿¡½ºÆ®·Î°Õ ¼ö¿ëü ºÐÇØÁ¦ ÀÓ»ó½ÃÇè °³¿ä

Á¦6Àå ¼±ÅÃÀû ¿¡½ºÆ®·Î°Õ ¼ö¿ëü ºÐÇØÁ¦(SERD) ÀÓ»ó½ÃÇè ÀλçÀÌÆ®

Á¦7Àå ½ÃÆÇ ¼±ÅÃÀû ¿¡½ºÆ®·Î°Õ ¼ö¿ëü ºÐÇØÁ¦(SERD)¿¡ °üÇÑ ÀλçÀÌÆ®

Á¦8Àå Faslodex - ÃÖÃÊ·Î ½ÃÆÇµÈ ¼±ÅÃÀû ¿¡½ºÆ®·Î°Õ ¼ö¿ëü ºÐÇØÁ¦

Á¦9Àå Á¦³×¸¯ Fulvestrant - °¡¿ë¼º ¹× °¡°Ý ºÐ¼®

Á¦10Àå Orserdu - µÎ ¹øÂ°·Î ½ÃÆÇµÈ ¼±ÅÃÀû ¿¡½ºÆ®·Î°Õ ¼ö¿ëü ºÐÇØÁ¦

Á¦11Àå °æÀï ±¸µµ

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Selective Estrogen Receptor Degrader (SERDs) Market Opportunity, Generic Availability, Drug Dosage, Price & Clinical Trials Insight 2030 Report Findings & Highlights:

Since the early 2000s, the landscape for Selective Estrogen Receptor Degraders (SERDs) has significantly changed, starting with the introduction of fulvestrant as the first in class drug. In contrast to previous endocrine therapies that only inhibited estrogen signaling, SERDs had a new edge by actively degrading the estrogen receptor. This not only stopped receptor activity but also limited the subsequent proliferation of hormone receptor-positive, HER2-negative breast cancer cells. As patients developed resistance to aromatase inhibitors and selective estrogen receptor modulators, SERDs soon became popular as a more effective and long-lasting therapeutic agent.

Fulvestrant, marketed under the brand name Faslodex by AstraZeneca, was the first SERD to be approved by regulatory authorities like US FDA. Initially used as a monotherapy for tamoxifen resistant patients, it soon gained popularity and was used in combination with other agents like CDK4/6 inhibitors. It grew over the years to become a mainstay therapy in HR+ postmenopausal breast cancer, owing to increasing clinical evidence and global uptake. The patent expiration of fulvestrant, however, brought about a significant change. The launch of generics in 2019 triggered a tide of affordable versions, significantly changing its market dynamics. With over 25 generics on the market worldwide, Faslodex market share has declined while generic fulvestrant use has skyrocketed, now representing over half of total usage.

This transition left an innovation gap that was addressed in 2023 with FDA approval of Orserdu (elacestrant), which was originally developed by Radius Health and then acquired by Menarini Group. What set Orserdu apart was its oral form, i.e., the first in the SERD class. It provided a convenient alternative to fulvestrant's intramuscular injection and was approved solely for a subpopulation of ESR1-mutation patients, who commonly become resistant to standard endocrine treatments. Orserdu's approval not only filled an evident clinical void but also reinvigorated interest in SERDs among pharmaceutical developers and clinicians.

The spotlight on oral SERDs such as Orserdu has set off a pipeline boom, as several next generation compounds find their way into mid to late stage clinical trials. Eli Lilly, Roche, AstraZeneca, and Olema Oncology are all pushing their own candidates, each trying to build on fulvestrant's limitations, such as poor bioavailability and short activity in patients with ESR1 mutations. Among the most promising of these candidates are imlunestrant, giredestrant, camizestrant, palazestrant, and taragarestrant, which all currently reside in late-phase testing. Several of these are not only being tested as monotherapies but also in combination with targeted therapies in an attempt to overcome multiple resistance pathways in advanced disease.

Perhaps the most technologically novel entries to this scene is vepdegestrant, a PROteolysis Targeting Chimera (PROTAC) drug co-developed by Arvinas and Pfizer. Instead of acting via classical receptor antagonism, vepdegestrant enlists the cell's native protein degradation machinery to degrade the estrogen receptor. With the completion of the successful Phase 3 VERITAC-2 trial, in June 2025 Pfizer and Arvinas filed an NDA seeking FDA approval. Vepdegestrant is set to be the first PROTAC-based SERD to hit the market, signaling a new frontier in targeted degradation therapy.

Beyond monotherapy use, the SERD platform is investigating combinations with other classes of agents including CDK4/6 inhibitors, PI3K inhibitors, and novel molecularly targeted agents. These strategies are designed to sustain the duration of response and prevent resistance pathways from outpacing treatment.

Although SERD development is presently centered on breast cancer, they are now gaining attention in other malignancies of the estrogen receptor-mediated nature, such as ovarian and endometrial cancers. Further, preclinical studies are investigating their use in non-oncologic applications like neuropsychiatric disorders, metabolic disorders, and chronic pain. Although these are in the initial stages, they are potential new frontiers.

The SERD market, while narrow in terms of approved medicines, has developed with rapid evolving into a dynamic and competitive landscape. With deep pipelines, sophisticated trial programs, and new technologies such as PROTACs, SERDs are already set to revolutionize the treatment landscape for hormone receptor-driven cancers and quite possibly much more.

Table of Contents

1. RESEARCH METHODOLOGY

2. Introduction to Selective Estrogen Receptor Degraders (SERDs)

3. Application Of Selective Estrogen Receptor Degraders By Indication

4. Selective Estrogen Receptor Degrader Market Analysis

5. Selective Estrogen Receptor Degrader Clinical Trials Overview

6. Selective Estrogen Receptor Degrader (SERD) Clinical Trials Insight

7. Marketed Selective Estrogen Receptor Degrader (SERD) Insight

8. Faslodex - 1st Commercially Available Selective Estrogen Receptor Degrader

9. Generic Fulvestrant - Availability & Price Analysis

10. Orserdu - 2nd Commercially Available Selective Estrogen Receptor Degrader

11. Competitive Landscape

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â